FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604205657> ?p ?o ?g. }

• W2604205657 abstract "Abstract Background Sodium-glucose co-transporter-2 inhibitors (SGLT2i) reduce glucose levels, body weight, and blood pressure, possibly resulting in cardiovascular protection. In phase III trials, SGLT2i were shown to increase HDL cholesterol. We aimed to evaluate whether the SGLT2i dapagliflozin affects HDL function in a randomized placebo-controlled trial. Methods Thirty-three type 2 diabetic patients were randomized to receive dapagliflozin 10 mg or placebo for 12 weeks on top of their glucose lowering medications. The primary end-point was the change in cholesterol efflux capacity (CEC) from macrophages at study end versus baseline. Secondary endpoints were changes in: distribution of HDL subfractions, lipid profile, activity of enzymes that mediate HDL antioxidant properties (PON1 and ARE) and cholesterol metabolism (CETP), HbA1c, body weight and composition. Results Thirty-one patients completed the study, n = 16 in the placebo group and n = 15 in the dapagliflozin group. Patients randomized to dapagliflozin were older and had lower adiposity indexes, although these differences disappeared after correction for multiple testing. Therapy with dapagliflozin reduced HbA1c by 0.9% and body weight by 3.1 kg, mainly attributable to reduction of body water and lean mass. As compared to placebo, dapagliflozin reduced CEC (−6.7 ± 2.4 versus 0.3 ± 1.8%; p = 0.043), but this effect was no longer significant after adjusting for age and BMI. No change was detected in HDL cholesterol, HDL subfractions, activity of PON1, ARE, and CETP. Conclusions Despite improvements in glucose control and reduction in body weight, therapy with dapagliflozin exerted no significant effect on HDL cholesterol levels and HDL functionality. Trial registration EudraCT 2014-004270-42; NCT02327039" @default.
• W2604205657 created "2017-04-14" @default.
• W2604205657 creator A5013598977 @default.
• W2604205657 creator A5027393457 @default.
• W2604205657 creator A5029164653 @default.
• W2604205657 creator A5037054820 @default.
• W2604205657 creator A5037147007 @default.
• W2604205657 creator A5045364954 @default.
• W2604205657 creator A5057218888 @default.
• W2604205657 creator A5088706650 @default.
• W2604205657 date "2017-04-04" @default.
• W2604205657 modified "2023-10-05" @default.
• W2604205657 title "Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial" @default.
• W2604205657 cites W1500436203 @default.
• W2604205657 cites W1545872968 @default.
• W2604205657 cites W1953794210 @default.
• W2604205657 cites W2000876672 @default.
• W2604205657 cites W2020659754 @default.
• W2604205657 cites W2025724423 @default.
• W2604205657 cites W2031730303 @default.
• W2604205657 cites W2039104561 @default.
• W2604205657 cites W2052161168 @default.
• W2604205657 cites W2052976889 @default.
• W2604205657 cites W2055823448 @default.
• W2604205657 cites W2059228589 @default.
• W2604205657 cites W2077636750 @default.
• W2604205657 cites W2093648180 @default.
• W2604205657 cites W2103844937 @default.
• W2604205657 cites W2105660444 @default.
• W2604205657 cites W2115220026 @default.
• W2604205657 cites W2121076428 @default.
• W2604205657 cites W2126919962 @default.
• W2604205657 cites W2139377033 @default.
• W2604205657 cites W2146264128 @default.
• W2604205657 cites W2155965977 @default.
• W2604205657 cites W2160088494 @default.
• W2604205657 cites W2165465852 @default.
• W2604205657 cites W2167245776 @default.
• W2604205657 cites W2261401807 @default.
• W2604205657 cites W2322578848 @default.
• W2604205657 cites W2338046714 @default.
• W2604205657 cites W2341932351 @default.
• W2604205657 cites W240522349 @default.
• W2604205657 cites W2412800896 @default.
• W2604205657 cites W2434919988 @default.
• W2604205657 cites W2462883443 @default.
• W2604205657 cites W2492672367 @default.
• W2604205657 cites W2515836370 @default.
• W2604205657 cites W2520011040 @default.
• W2604205657 cites W2557102596 @default.
• W2604205657 cites W2559018178 @default.
• W2604205657 doi "https://doi.org/10.1186/s12933-017-0529-3" @default.
• W2604205657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5379610" @default.
• W2604205657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28376855" @default.
• W2604205657 hasPublicationYear "2017" @default.
• W2604205657 type Work @default.
• W2604205657 sameAs 2604205657 @default.
• W2604205657 citedByCount "75" @default.
• W2604205657 countsByYear W26042056572017 @default.
• W2604205657 countsByYear W26042056572018 @default.
• W2604205657 countsByYear W26042056572019 @default.
• W2604205657 countsByYear W26042056572020 @default.
• W2604205657 countsByYear W26042056572021 @default.
• W2604205657 countsByYear W26042056572022 @default.
• W2604205657 countsByYear W26042056572023 @default.
• W2604205657 crossrefType "journal-article" @default.
• W2604205657 hasAuthorship W2604205657A5013598977 @default.
• W2604205657 hasAuthorship W2604205657A5027393457 @default.
• W2604205657 hasAuthorship W2604205657A5029164653 @default.
• W2604205657 hasAuthorship W2604205657A5037054820 @default.
• W2604205657 hasAuthorship W2604205657A5037147007 @default.
• W2604205657 hasAuthorship W2604205657A5045364954 @default.
• W2604205657 hasAuthorship W2604205657A5057218888 @default.
• W2604205657 hasAuthorship W2604205657A5088706650 @default.
• W2604205657 hasBestOaLocation W26042056571 @default.
• W2604205657 hasConcept C126322002 @default.
• W2604205657 hasConcept C134018914 @default.
• W2604205657 hasConcept C142724271 @default.
• W2604205657 hasConcept C168563851 @default.
• W2604205657 hasConcept C204787440 @default.
• W2604205657 hasConcept C27081682 @default.
• W2604205657 hasConcept C2777180221 @default.
• W2604205657 hasConcept C2777422806 @default.
• W2604205657 hasConcept C2778163477 @default.
• W2604205657 hasConcept C2780473172 @default.
• W2604205657 hasConcept C511355011 @default.
• W2604205657 hasConcept C544821477 @default.
• W2604205657 hasConcept C555293320 @default.
• W2604205657 hasConcept C71924100 @default.
• W2604205657 hasConceptScore W2604205657C126322002 @default.
• W2604205657 hasConceptScore W2604205657C134018914 @default.
• W2604205657 hasConceptScore W2604205657C142724271 @default.
• W2604205657 hasConceptScore W2604205657C168563851 @default.
• W2604205657 hasConceptScore W2604205657C204787440 @default.
• W2604205657 hasConceptScore W2604205657C27081682 @default.
• W2604205657 hasConceptScore W2604205657C2777180221 @default.
• W2604205657 hasConceptScore W2604205657C2777422806 @default.
• W2604205657 hasConceptScore W2604205657C2778163477 @default.
• W2604205657 hasConceptScore W2604205657C2780473172 @default.
• W2604205657 hasConceptScore W2604205657C511355011 @default.

• next